Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rockwood K et al. – Despite evidence that links cognitive impairment to vascular risk factors, only a minority of clinical practice guidelines for the treatment of vascular risk factors consider cognition as either an adverse outcome or as a factor to consider in treatment.


Exclusive Author Commentary
Kenneth Rockwood, 11/06/09

The reason to treat vascular risk factors is to avoid damage to target organs, including the brain. Conventionally, such damage has been conceived of as stroke, especially motoric strokes. Cognition is also affected by vascular risk factors, but for historical reasons, has received much less recognition. This paper shows that most vascular risk factor guidelines ignore the impact on cognition. It notes too that cognitive impairment in this at risk group might affect medication adherence – and thereby increase risk. Perhaps now that the Hypertension in the Very Elderly Trial data have drawn attention to cognition and hypertension, we might see a change. For now, however, we are left with the vicious cycle of cognition not being studied in trials, so that we have little data about it, so that it is ignored in evidence-based clinical practice guidelines. This is just one example of how “evidence based” often is indistinguishable from “evidence-biased”.

   

Today in Geriatrics...keeping you current

Acute medical management of the non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in older patients
Archives of Gerontology and Geriatrics, 10/14/09

Approach to Thrombocytopenia in Older Adults
Geriatrics & Aging, 11/10/09

Vitamin D insufficiency and health outcomes over 5 y in older women
American Journal of Clinical Nutrition, 11/13/09

Today in Neurology...keeping you current

Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Today in Vascular Medicine...keeping you current

Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09

Vitamin D and cardiovascular disease
Current Atherosclerosis Reports, 11/12/09

Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address